Back
Incyte Corp. 10K Form
Buy
57
INCY
Incyte Corp.
Last Price:
$101.09
Seasonality Move:
-4.52%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-04-30 | 10Q | INCY/Incyte Corp. Quarterly |
| 2023-10-31 | 10Q | INCY/Incyte Corp. Quarterly |
| 2023-08-01 | 10Q | INCY/Incyte Corp. Quarterly |
| 2023-05-02 | 10Q | INCY/Incyte Corp. Quarterly |
| 2022-11-01 | 10Q | INCY/Incyte Corp. Quarterly |
| 2022-08-02 | 10Q | INCY/Incyte Corp. Quarterly |
Receive INCY News And Ratings
See the #1 stock for the next 7 days that we like better than INCY
INCY Financial Statistics
Sales & Book Value
| Annual Sales: | $5.1B |
|---|---|
| Cash Flow: | $521.4M |
| Price / Cash Flow: | 15.27 |
| Annual Sales: | $26.04 |
| Price / Book: | 3.89 |
Profitability
| EPS (TTM): | 6.40340 |
|---|---|
| Net Income (TTM): | $1.3B |
| Gross Margin: | $4.7B |
| Return on Equity: | 30.48% |
| Return on Assets: | 21.19% |
Incyte Corp. Earnings Forecast
Key Incyte Corp. Financial Ratios
-
The Gross Profit Margin over the past 33 years for INCY is 91.47%.
-
The Selling, General & Administrative Expenses for INCY have been equal to 0.00% of Gross Profit Margin.
-
The Research & Development expenses have been 38.58% of Revenue.
-
The Interest Expense is 0.19% of Operating Income.
-
The Net Earning history of INCY is 25.03% of Total Revenues.
-
Per Share Earnings over the last 33 years have been positive in 16 years.
Incyte Corp. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | INCY |
| CUSIP: | 45337C |
| Website: | incyte.com |
Debt
| Debt-to-Equity Ratio: | 0.01 |
|---|---|
| Current Ratio: | 3.32 |
| Quick Ratio: | 3.04 |
Price-to-Earnings
| Trailing P/E Ratio: | 15.77 |
|---|---|
| Forward P/E Ratio: | 11.41 |
INCY Technical Analysis vs Fundamental Analysis
Buy
57
Incyte Corp. (INCY)
is a Buy
Is Incyte Corp. a Buy or a Sell?
-
Incyte Corp. stock is rated a BuyThe current Incyte Corp. [INCY] share price is $101.10. The Score for INCY is 57, which is 14% above its historic median score of 50, and infers lower risk than normal.